Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 plus carboplatin + paclitaxel vs carboplatin + paclitaxel in first-line treatment of recurrent/metastatic endometrial cancer
ChiCTR2600115942Phase 2Not yet recruiting
- Sponsor
- Nantong Cancer Hospital
- Start
- Jan 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of QL1706 in endometrial cancer (EC) (2 arms), sponsored by Nantong Cancer Hospital. Primary endpoint: Objective Response Rate. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
QL1706
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on ChiCTR2600115942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600115942.